karxt bristol myers squibb news

Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of Schizophrenia. See why BMY stock is a Buy.

MarketWatch on MSN · 14h

Bristol-Myers Squibb stock jumps on schizophrenia drug approval

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia drug.

Reuters · 14h

Bristol Myers wins US FDA approval for new type of schizophrenia drug

The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades.

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential

Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...

WVTF26m

A new kind of drug for schizophrenia promises fewer side effects

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Bristol-Myers Squibb: Sell Rating Justified by Market Challenges and Drug Uptake Concerns

Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb (BMY – Research Report). The associated ...

Palm Beach Post3h

This FDA-approved drug promises a new way to treat schizophrenia

Studies showed Bristol Myers Squibb's drug, KarXT, improved symptoms of schizophrenia and led to fewer side effects than existing antipsychotic treatments. Researchers are optimistic patients ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results